Troponin in diabetic patients with and without chronic coronary artery disease.

PubWeight™: 0.77‹?›

🔗 View Article (PMC 4508806)

Published in BMC Cardiovasc Disord on July 21, 2015

Authors

Carlos Alexandre Wainrober Segre1, Whady Hueb2, Rosa Maria Rahmi Garcia3, Paulo Cury Rezende4, Desiderio Favarato5, Celia Maria Cassaro Strunz6, Marília da Costa Oliveira Sprandel7, Alessandra Roggério8, Ana Luiza de Oliveira Carvalho9, Raul Cavalcante Maranhão10, José Antonio Franchini Ramires11, Roberto Kalil Filho12

Author Affiliations

1: Department of Clinical Cardiology, Heart Institute (InCor) University of São Paulo, Av. Dr. Eneas de Carvalho Aguiar 44, AB, BL I, Sala 114, Cerqueira César, Sao Paulo, SP, 05403-000, Brazil. alexandre.segre@terra.com.br.
2: Department of Clinical Cardiology, Heart Institute (InCor) University of São Paulo, Av. Dr. Eneas de Carvalho Aguiar 44, AB, BL I, Sala 114, Cerqueira César, Sao Paulo, SP, 05403-000, Brazil. whady.hueb@incor.usp.br.
3: Department of Clinical Cardiology, Heart Institute (InCor) University of São Paulo, Av. Dr. Eneas de Carvalho Aguiar 44, AB, BL I, Sala 114, Cerqueira César, Sao Paulo, SP, 05403-000, Brazil. rosarahmi@gmail.com.
4: Department of Clinical Cardiology, Heart Institute (InCor) University of São Paulo, Av. Dr. Eneas de Carvalho Aguiar 44, AB, BL I, Sala 114, Cerqueira César, Sao Paulo, SP, 05403-000, Brazil. rezendepaulo@hotmail.com.
5: Department of Clinical Cardiology, Heart Institute (InCor) University of São Paulo, Av. Dr. Eneas de Carvalho Aguiar 44, AB, BL I, Sala 114, Cerqueira César, Sao Paulo, SP, 05403-000, Brazil. desideriofavarato2010@gmail.com.
6: Department of Clinical Cardiology, Heart Institute (InCor) University of São Paulo, Av. Dr. Eneas de Carvalho Aguiar 44, AB, BL I, Sala 114, Cerqueira César, Sao Paulo, SP, 05403-000, Brazil. labcelia@incor.usp.br.
7: Department of Clinical Cardiology, Heart Institute (InCor) University of São Paulo, Av. Dr. Eneas de Carvalho Aguiar 44, AB, BL I, Sala 114, Cerqueira César, Sao Paulo, SP, 05403-000, Brazil. marilia_coliveira@yahoo.com.br.
8: Department of Clinical Cardiology, Heart Institute (InCor) University of São Paulo, Av. Dr. Eneas de Carvalho Aguiar 44, AB, BL I, Sala 114, Cerqueira César, Sao Paulo, SP, 05403-000, Brazil. alessandra.roggerio@incor.usp.br.
9: Department of Clinical Cardiology, Heart Institute (InCor) University of São Paulo, Av. Dr. Eneas de Carvalho Aguiar 44, AB, BL I, Sala 114, Cerqueira César, Sao Paulo, SP, 05403-000, Brazil. analuacatita@hotmail.com.
10: Department of Clinical Cardiology, Heart Institute (InCor) University of São Paulo, Av. Dr. Eneas de Carvalho Aguiar 44, AB, BL I, Sala 114, Cerqueira César, Sao Paulo, SP, 05403-000, Brazil. ramarans@usp.br.
11: Department of Clinical Cardiology, Heart Institute (InCor) University of São Paulo, Av. Dr. Eneas de Carvalho Aguiar 44, AB, BL I, Sala 114, Cerqueira César, Sao Paulo, SP, 05403-000, Brazil. jramires@incor.usp.br.
12: Department of Clinical Cardiology, Heart Institute (InCor) University of São Paulo, Av. Dr. Eneas de Carvalho Aguiar 44, AB, BL I, Sala 114, Cerqueira César, Sao Paulo, SP, 05403-000, Brazil. roberto.kalil@incor.usp.br.

Articles cited by this

Global and societal implications of the diabetes epidemic. Nature (2001) 25.18

Diabetes and cardiovascular disease. The Framingham study. JAMA (1979) 11.95

Oxidative stress and diabetic complications. Circ Res (2010) 9.37

Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med (2009) 8.05

Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation (1999) 8.04

Apoptosis in the failing human heart. N Engl J Med (1997) 6.35

Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA (2010) 6.11

A sensitive cardiac troponin T assay in stable coronary artery disease. N Engl J Med (2009) 5.81

Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. JAMA (2010) 5.37

Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study. Circulation (2011) 4.78

HDL cholesterol and other lipids in coronary heart disease. The cooperative lipoprotein phenotyping study. Circulation (1977) 4.47

Prevalence and determinants of troponin T elevation in the general population. Circulation (2006) 2.84

Sex, age, cardiovascular risk factors, and coronary heart disease: a prospective follow-up study of 14 786 middle-aged men and women in Finland. Circulation (1999) 2.78

Analytical characteristics of high-sensitivity cardiac troponin assays. Clin Chem (2011) 2.51

A new season for cardiac troponin assays: it's time to keep a scorecard. Clin Chem (2009) 2.07

Recommendations for the use of cardiac troponin measurement in acute cardiac care. Eur Heart J (2010) 1.88

Determinants of troponin release in patients with stable coronary artery disease: insights from CT angiography characteristics of atherosclerotic plaque. Heart (2010) 1.87

Glycemic control and complications in type 2 diabetes mellitus. Am J Med (2010) 1.69

Prognostic value of cardiac troponin I measured with a highly sensitive assay in patients with stable coronary artery disease. J Am Coll Cardiol (2013) 1.65

Sensitive cardiac troponin T assay and the risk of incident cardiovascular disease in women with and without diabetes mellitus: the Women's Health Study. Circulation (2011) 1.47

Troponin elevation in heart failure prevalence, mechanisms, and clinical implications. J Am Coll Cardiol (2010) 1.43

Prevention Conference VI: Diabetes and Cardiovascular Disease: Writing Group II: pathogenesis of atherosclerosis in diabetes. Circulation (2002) 1.43

Chronic hyperglycemia impairs endothelial function and insulin sensitivity via different mechanisms in insulin-dependent diabetes mellitus. Circulation (1996) 1.26

High-sensitive troponin T measurements: what do we gain and what are the challenges? Eur Heart J (2012) 1.12

Determinants and prognostic implications of cardiac troponin T measured by a sensitive assay in type 2 diabetes mellitus. Cardiovasc Diabetol (2010) 1.07

Diabetes mellitus and thrombosis. Thromb Res (2011) 1.04

The extent of coronary atherosclerosis is associated with increasing circulating levels of high sensitive cardiac troponin T. Arterioscler Thromb Vasc Biol (2010) 1.02

High-sensitive cardiac troponin T and its relations to cardiovascular risk factors, morbidity, and mortality in elderly men. Am Heart J (2013) 1.00

Revascularization for coronary artery disease in diabetes mellitus: angioplasty, stents and coronary artery bypass grafting. Rev Endocr Metab Disord (2010) 0.90

New features of troponin testing in different clinical settings. J Intern Med (2010) 0.89

High-sensitivity cardiac troponin for screening large populations of healthy people: is there risk? Clin Chem (2011) 0.84

Heart in diabetes: a microvascular disease. Diabetes Care (2011) 0.83

Predictive value of high-sensitivity troponin-I for future adverse cardiovascular outcome in stable patients with type 2 diabetes mellitus. Cardiovasc Diabetol (2014) 0.82

Blood glucose and risk of coronary heart disease. Arteriosclerosis (1981) 0.82

Serial measurements of high-sensitivity cardiac troponin T after exercise stress test in stable coronary artery disease. Biomarkers (2013) 0.80

Diffuse coronary disease: short- and long-term outcome after percutaneous coronary intervention. Acta Cardiol (2013) 0.80

Diagnostic accuracy of sensitive or high-sensitive troponin on presentation for myocardial infarction: a meta-analysis and systematic review. Vasc Health Risk Manag (2014) 0.79

High-sensitivity cardiac troponin T and N-terminal pro-B-type natriuretic peptide predict mortality in stable coronary artery disease: results from the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Clin Chem Lab Med (2013) 0.78

Clinical course and outcomes of type-2 diabetic patients after treatment intensification for insufficient glycaemic control - results of the 2 year prospective DiaRegis follow-up. BMC Cardiovasc Disord (2014) 0.77